Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL

This article was originally published here

The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a

The post Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply